Table 3.
Hazard ratio (95% CI) | P-value | |
---|---|---|
Age (years) | 1.046 (1.026, 1.066) | 3.1E-06 |
Sex (Female) | 0.71 (0.43, 1.15) | 0.17 |
Fever | 2.77 (1.31, 5.85) | 0.007 |
Cough | 1.32 (0.81, 2.18) | 0.26 |
Fatigue | 1.24 (0.77, 2.00) | 0.37 |
Respiratory symptom | 1.34 (0.59, 3.05) | 0.48 |
Cardiovascular disease history | 3.91 (1.82, 8.38) | 0.0004 |
Arbidol* | 0.28 (0.084, 0.90) | 0.033 |
Ribavirin | 0.53 (0.24, 1.16) | 0.11 |
IFN-α* | 0.30 (0.15, 0.58) | 0.0005 |
Lopinavir–ritonavir | 0.54 (0.28, 1.01) | 0.055 |
Survival analysis was performed to test the association between the primary outcome and drug use by the Cox proportional hazard model. Risk factors includes age, sex, clinical symptoms, disease history were adjusted